| Name | Title | Contact Details |
|---|
Altruista Health provides a suite of technology solutions that support collaborative, data-driven and person-centered approaches to population health management. Founded in 2007, Altruista Health has been recognized by Gartner as one of the fastest-growing care management technology companies serving complex care populations. Today, our solutions remove barriers to care, reduce avoidable healthcare expenses and improve health outcomes for more than 38 million people. Our GuidingCare™ platform is a web-based population health management system that enables health plans to maximize the value of their data and improve the quality of care for high-risk members. GuidingCare integrates data from a variety of systems, including medical and pharmacy claims, EMR/EHR, eligibility, HIEs and others, to power role-optimized workflow management tools for care coordination, quality improvement, care transitions management, utilization management, LTC/long term support services and more.
Cayuga Medical Center is a 204-bed, state-of-the art regional medical center. The Medical Center’s mission is to deliver the highest quality health care and is affiliated with many prestigious health care organizations including Cornell University's Weill Medical College in New York City, Roswell Park Cancer Institute in Buffalo, NY, Rochester General Hospital’s Heart Institute and the Mayo Medical Laboratories. CMC received a silver award for “The Center Is You” campaign that rolled out in 2008.
Aequor Healthcare is a Piscataway, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.